Projects

View
Name Pharma-Cog
Long Name Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
Description When it comes to Alzheimer’s disease (AD), most potential drug candidates fail during clinical trials, resulting in significant setbacks in the development of effective treatments. IMI’s Pharma-Cog project set out to change that. The project developed a matrix of biomarkers which can be used to study the effect of a drug candidate both in animals and humans, and has the potential to more accurately predict the success of future drugs in early stages of drug development. Pharma-Cog scientists also found a better way to stratify patients with early signs of Alzheimer’s disease, which may lead to more definitive clinical trials. All this has the potential to help pharmaceutical companies conduct more efficient and more precise clinical trials in the future, speeding up the development of AD drugs. At least one biotech company is already using the results of Pharma-Cog to test a promising new drug candidate.
Objectives 1) Identification and validation of healthy subject models of cognitive impairment to support early proof-of-efficacy studies 2) Development and validation of pharmacodynamic markers suitable to support the determination of efficacious dose ranges 3) Identification of markers sensitive to early disease progression and development of animal models with greater predictive value
Website https://www.alzheimer-europe.org/Research/PharmaCog
Start date 01-01-2010
End date 31-12-2015
Logo
Name Projects Type of institution Country  
Janssen Pharmaceutica NV EPAD ADAPTED AMYPAD IMPRiND EQIPD NEURONET EMIF IM2PACT PHAGO PRISM RADAR-CNS RADAR-AD ROADMAP IDEA-FAST Pharma-Cog EFPIA Belgium
Alzheimer Europe EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD ROADMAP NEURONET Pharma-Cog Patient/carers organisation Luxembourg
Eli Lilly And Company Ltd EPAD IMPRiND MOPEAD PHAGO PRISM RADAR-AD ROADMAP NEURONET IDEA-FAST Pharma-Cog EFPIA United Kingdom
F. Hoffmann-La Roche AG EPAD EQIPD EMIF PHAGO PRISM ROADMAP NEURONET IDEA-FAST Pharma-Cog EFPIA Switzerland
Eisai Inc EPAD PHAGO Pharma-Cog EFPIA United States
H. Lundbeck As EPAD IMPRiND IM2PACT PD-MitoQUANT PHAGO RADAR-CNS ROADMAP Pharma-Cog EFPIA Denmark
Novartis Pharma AG EPAD IMPRiND EQIPD AETIONOMY IM2PACT PRISM RADAR-AD ROADMAP Mobilise-D Pharma-Cog EFPIA Switzerland
UCB Biopharma SPRL EPAD EQIPD AETIONOMY EMIF PD-MitoQUANT RADAR-CNS IDEA-FAST Pharma-Cog EFPIA Belgium
Institut National De La Sante Et De La Recherche Medicale EPAD EMIF Pharma-Cog Academia France
Boehringer Ingelheim International Gmbh PRISM EPAD EQIPD AETIONOMY EMIF Pharma-Cog PRISM2 EFPIA Germany
University Of Exeter PRISM EMIF PD-MIND Pharma-Cog Academia United Kingdom
Institut De Recherches Servier IMPRiND EMIF EQIPD Pharma-Cog Academia France
Centre National De La Recherche Scientifique CNRS IMPRiND PD-MitoQUANT Pharma-Cog Academia France
Merck Kommanditgesellschaft Auf Aktien EMIF Mobilise-D Pharma-Cog EFPIA Germany
Consorci Institut d'Investigacions Biomèdiques August Pi I Sunyer AETIONOMY Pharma-Cog Academia Spain
Astrazeneca AB MOPEAD PHAGO Mobilise-D IDEA-FAST PD-MIND Pharma-Cog EFPIA Sweden
Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio - Fatebenefratelli RADAR-CNS EMIF Pharma-Cog Academia Italy
Université D'Aix-Marseille AETIONOMY Pharma-Cog Academia France
Glaxosmithkline Research And Development Ltd EMIF Pharma-Cog EFPIA United Kingdom
Universität Leipzig EMIF Pharma-Cog Academia Germany
Universite Paul Sabatier Toulouse III EMIF Pharma-Cog Academia France
Fondazione Sdn Per La Ricerca E L'Alta Formazione In Diagnostica Nucleare Pharma-Cog Academia Italy
Istituto Di Ricerche Farmacologiche Mario Negri Pharma-Cog Academia Italy
Stichting Vu Pharma-Cog Academia Netherlands
Universidad De Murcia Pharma-Cog Academia Spain
Universita Cattolica Del Sacro Cuore Pharma-Cog Academia Italy
Universita Degli Studi Di Foggia Pharma-Cog Academia Italy
Universita Degli Studi Di Genova Pharma-Cog Academia Italy
Universita Degli Studi Di Perugia Pharma-Cog Academia Italy
Universita Degli Studi Di Verona Pharma-Cog Academia Italy
Universitätsklinikum Essen Pharma-Cog Academia Germany
Université De Lille II Pharma-Cog Academia France
Diaxonhit SA Pharma-Cog SME France
Innovative Concepts in Drug Development (ICDD-sas) Pharma-Cog SME France
Qualissima, France Pharma-Cog SME France
SAS Alzprotect Pharma-Cog SME France
Elliniki Etairia Nosoy Alzheimer Kai Syggenon Diatarachon Somateio, Thessaloniki Pharma-Cog Patient/carers organisation Greece
Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux Marseille Pharma-Cog Other France
Centre Hospitalier Regional Et Universitaire De Lille Pharma-Cog Other France
Museum National D'Histoire Naturelle Pharma-Cog Other France
WP number Description Project  
WP1 Development and validation of translatable provocation challenge models (Clinical studies) Pharma-Cog
WP2 Development and validation of translatable provocation challenge models (Pre-clinical studies) Pharma-Cog
WP3 Development and validation of translatable pharmacodynamic markers (Clinical studies) Pharma-Cog
WP4 Development and validation of translatable pharmacodynamic markers (Pre-clinical studies) Pharma-Cog
WP5 Identification of biomarkers sensitive to disease progression (Clinical Studies) Pharma-Cog
WP6 Characterisation of transgenics and development of imaging, electrophysiological, and biological markers for disease-modifying drugs (Animal studies) Pharma-Cog
WP7 DMPK & PK/PD Pharma-Cog
WP8 Statistical modelling of multi-model variable Pharma-Cog
WP9 Project Management & IPR Pharma-Cog
WP10 Communication, dissemination and ethics Pharma-Cog
Deliverable number Title Project Submission date Link Keywords  
No entries in table
Title First author last name Year Project Link Keywords  
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment Lorenzi 2010 Pharma-Cog https://doi.org/10.1016/j.neurobiolaging.2010.04.036 Mild cognitive impairment, Conversion, Marker disease, Clinical trials, Enrichment
Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease Babiloni 2011 Pharma-Cog https://doi.org/10.1016/j.clinph.2011.03.029 Parkinson’s disease (PD), Dementia, Resting-state electroencephalography (EEG), Low-resolution brain electromagnetic source tomography (LORETA), Brain rhythms, Alpha
Disease Tracking Markers for Alzheimer’s Disease at the Prodromal (MCI) Stage Drago 2011 Pharma-Cog https://doi.org/10.3233/jad-2011-0043 Alzheimer's disease, Mild cognitive impairment, neuropsychology, neuroimaging, diffusion tensor imaging, functional MRI, spectroscopy, positron emission tomography, EEG, cerebrospinal fluid
Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study Babiloni 2011 Pharma-Cog https://doi.org/10.3233/jad-2011-101710 Alzheimer's disease, Alzheimer's disease neuroimaging initiative, amnesic mild c cognitive impairment, electroencephalographic rhythms, low resolution brain electromagnetic tomography, magnetic resonance imaging, resting state, white matter vascular lesion
Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: an electroencephalographic study Babiloni 2011 Pharma-Cog https://doi.org/10.1002/hbm.21157 mild cognitive impairment, Alzheimer's disease, electroencephalography, alpha rhythms, low‐resolution brain electromagnetic tomography, cognitive decline
The grey mouse lemur: A non-human primate model for ageing studies Languille 2011 Pharma-Cog https://doi.org/10.1016/j.arr.2011.07.001 Ageing, Age-related disease, Lifespan, Microcebus murinus
Animal Models of Alzheimer’s Disease and Drug Development Laurijssens 2012 Pharma-Cog http://dx.doi.org/10.1016/j.ddtec.2012.04.001 alzheimer, treatments, hypotheses, patients, tools, animal, drugs
Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients Babiloni 2012 Pharma-Cog https://doi.org/10.1016/j.clinph.2012.09.017 Electroencephalography (EEG), Drug treatments, Alzheimer’s disease
Effects of Dietary Resveratrol on the Sleep-Wake Cycle in the Non-HumanPrimate Gray Mouse Lemur (Microcebus murinus) Pifferi 2012 Pharma-Cog http://dx.doi.org/10.3109/07420528.2011.654019 Circadian rhythms, Electroencephalography, Metabolism, Microcebus, murinus, Resveratrol, Sleep
Worldwide Alzheimer's disease neuroimaging initiative Carrillo 2012 Pharma-Cog https://doi.org/10.1016/j.jalz.2012.04.007 Alzheimer's disease, neuroimaging, biomarkers
A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans Marizzoni 2013 Pharma-Cog https://doi.org/10.1016/j.ddstr.2013.09.003 Memory, Alzheimer, Paradigm, neuroimaging
Animal models of Alzheimer's disease and drug development Laurijssens 2013 Pharma-Cog https://doi.org/10.1016/j.ddtec.2012.04.001 Animal models, alzheimer, drug development
Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations Jovicich 2013 Pharma-Cog https://doi.org/10.1016/j.neuroimage.2013.05.007 Brain morphometry; Multi-center; Multi-site MRI; Reliability; Reproducibility; Structural MRI
Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents Bablioni 2013 Pharma-Cog https://doi.org/10.1016/j.clinph.2012.07.023 Electroencephalography, EEG, Neurodegeneration, Animal models, Drug treatments
Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans Deguil 2013 Pharma-Cog https://doi.org/10.1016/j.ddtec.2013.03.003 Alzheimer, Pharmacodynamic, biomarker, validationm, review
Experimental sleep deprivation as a tool to test memory deficits in rodents Colavito 2013 Pharma-Cog https://dx.doi.org/10.3389%2Ffnsys.2013.00106 Sleep, sleep-deprivation, memory, learning, cognitive impairment, Alzheimer's disease, rat, mouse
Octodon degus: A Model for the Cognitive Impairment Associated with Alzheimer's Disease Tarragon 2013 Pharma-Cog http://dx.doi.org/10.1111/cns.12125 Alzheimer disease, Amyloid beta-protein, Memory, Mild Cognitive Impairment
Alzheimer disease, Amyloid beta-protein, Memory, Mild Cognitive Impairment Rahman 2013 Pharma-Cog https://doi.org/10.1371/journal.pone.0064493 Sleep, Lemurs, Cognitive impairment, Learning, Alzheimer's disease, Primates, Spatial memory, Rodents,
Alpha-Theta Effects Associated with Ageing during the Stroop Test Nombela 2014 Pharma-Cog https://doi.org/10.1371/journal.pone.0095657 Stroop, Alpha, Theta, ageing
Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus Tarragon 2014 Pharma-Cog https://doi.org/10.1016/j.neuropharm.2014.05.023 Alzheimer disease; Memantine; Memory; Octodon degus; Sleep deprivation.
Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects Jovicich 2014 Pharma-Cog https://doi.org/10.1016/j.neuroimage.2014.06.075 Brain diffusion tensor imaging, Reproducibility, Reliability, Tract-based spatial statistics, Multi-center, Multi-site MRI
Deficits of psychomotor and mnesic functions across aging in mouse lemur primates Languille 2015 Pharma-Cog https://doi.org/10.3389/fnbeh.2014.00446 psychomotor, anxiety, working memory, spatial memory, recognition memory
Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly Marizzoni 2015 Pharma-Cog https://doi.org/10.1002/hbm.22859 Freesurfer; hippocampus; test-retest reproducibility; within session T1 averaging.
On-Going Frontal Alpha Rhythms Are Dominant in Passive State and Desynchronize in Active State in Adult Gray Mouse Lemurs Infarinato 2015 Pharma-Cog https://doi.org/10.1371/journal.pone.0143719 Lemur, Alpha, EEG, intervention
P1-158: Spectral ongoing eeg markers of motor activity in mouse models in physiological aging and Alzheimer's disease Babiloni 2015 Pharma-Cog https://doi.org/10.1016/j.jalz.2015.06.357 BEG. EEG, mice, Alzheimer
Retinal aging in the diurnal Chilean rodent (Octodon degus): histological, ultrastructural and neurochemical alterations of the vertical information processing pathway Szabadfi 2015 Pharma-Cog https://doi.org/10.3389/fncel.2015.00126 Octodon degus; aging; retina; rod bipolar cells; synaptic proteins; ultrastructure; vertical pathway.
The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice Balducci 2015 Pharma-Cog https://doi.org/10.3233/jad-150029 Alzheimer’s disease; TASTPM mice; amyloid-β; apolipoprotein E; bexarotene; magnetic resonance imaging; memory; therapy.
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ Galluzzi 2016 Pharma-Cog https://doi.org/10.1111/joim.12482 biomarkers, electroencephalography, magnetic resonance imaging, mild cognitive impairment
Free water elimination using a bi-tensor model improves test-retest reproducibility of diffusion tensor imaging indices in the brain Albi 2016 Pharma-Cog https://doi.org/10.1002/hbm.23350 brain diffusion tensor imaging; free-water imaging; healthy elderly; longitudinal; multisite diffusion MRI; test-retest reproducibility.
Impaired fasting blood glucose is associated to cognitive impairment and cerebral atrophy in middle-aged non-human primates Djelti 2016 Pharma-Cog https://doi.org/10.18632/aging.101148 blood glucose, middle age, spatial memory performance, hippocampal/septal atrophy, spontaneous models, Microcebus murinus
Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study Jovicich 2016 Pharma-Cog https://doi.org/10.1016/j.neuroimage.2015.07.010 Default Mode Network; Functional connectivity; Multi-center; Multi-site MRI; Reproducibility.
Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques Marchitelli 2016 Pharma-Cog https://doi.org/10.1002/hbm.23157 default mode network; independent component analysis; multisite; physiological noise correction; resting-state networks; task-free fMRI; test-retest reliability.
The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model Deleye 2016 Pharma-Cog https://doi.org/10.1177/1536012115624919 mouse, brain PET, SUV, 18F-FDG, Alzheimer
Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model Waldron 2017 Pharma-Cog http://doi.org/10.3233/jad-160760 Alzheimer’s disease, [18F]-AV45, [18F]-FDG, longitudinal, small animal imaging, transgenic mice
On-going electroencephalographic rhythms related to cortical arousal in wild-type mice: the effect of aging Del Percio 2017 Pharma-Cog https://doi.org/10.1016/j.neurobiolaging.2016.09.004 Electroencephalographic (EEG) rhythms, C57 wild-type (WT) mice, Awake active state, Awake passive state
Adaptability and reproducibility of a memory disruption rTMS protocol in the PharmaCog IMI European project Martin-Trias 2018 Pharma-Cog https://doi.org/10.1038/s41598-018-27502-1 TMS, rTMS, memory
Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential? Gil-Martínez 2018 Pharma-Cog https://doi.org/10.1186/s12974-018-1357-4 Parkinsonism, Neuroinflammation, Oxidative stress, Physical activity, Microglia, Astrocytes, S100b
Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers Marizzoni 2018 Pharma-Cog https://doi.org/10.3233/jad-180152 Alzheimer’s disease, biomarkers, clinical trial, magnetic resonance imaging, mild cognitive impairment, precision medicine
Unexpected Exacerbation of Neuroinflammatory Response After a Combined Therapy in Old Parkinsonian Mice Gil-Martínez 2018 Pharma-Cog https://doi.org/10.3389/fncel.2018.00451 Parkinsonism; aging; drug-repositioning; glia; neuroinflammation; oxidative stress.
CSF cutoffs for MCI due to AD depend on APOEε4 carrier status Marizzoni 2019 Pharma-Cog https://doi.org/10.1016/j.neurobiolaging.2019.12.019 Alzheimer's disease, Apolipoprotein E, Mild cognitive impairment, CSF cutoff, Disease progression
Local Gastrointestinal Injury Exacerbates Inflammation and Dopaminergic Cell Death in Parkinsonian Mice Gil-Martínez 2019 Pharma-Cog https://doi.org/10.1007/s12640-019-0010-z Parkinson’s disease, Ulcerative colitis, Systemic inflammation, Neurodegeneration
One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI) Frisoni 2019 Pharma-Cog https://doi.org/10.3233/jad-190267 Alzheimer’s disease, biomarkers, clinical trial, magnetic resonance imaging, mild cognitive impairment, precision medicine
Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study Albani 2019 Pharma-Cog https://doi.org/10.3233/jad-180321 Amnesic mild cognitive impairment; PharmaCog project; amyloid-beta peptide; biomarkers; clinical trial; clusterin; prodromal Alzheimer’s disease.
Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Jovicich 2019 Pharma-Cog https://doi.org/10.3233/jad-180158 Alpha rhythms; PharmaCog project; amnesic mild cognitive impairment; biomarkers; clinical trial; electroencephalography; functional magnetic resonance imaging; oddball event-related potentials; prodromal Alzheimer’s disease; resting state.
A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages Abate 2020 Pharma-Cog http://doi.org/10.3390/jpm11010014 blood-based biomarker, Alzheimer’s disease, machine learning, β-amyloid, conformation variant of p53
Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors Quattrini 2020 Pharma-Cog https://doi.org/10.1016/j.neuroimage.2020.116932 Amygdalar nuclei, Hippocampal subfields, Multicenter MRI study, FreeSurfer, Reliability analysis
Identification of differentially expressed genes profiles in a combined mouse model of Parkinsonism and colitis Gil-Martínez 2020 Pharma-Cog https://doi.org/10.1038/s41598-020-69695-4 Parkinson, gene, mice
Title Description Type Project  
No entries in table

 

Back to list